Developer of an organ-targeted positron emission tomography (PET) imaging system designed for high-definition and low-dose applications in oncology, neurology, and cardiology. The company's technology has ten times the efficiency for detecting radiotracer compared to traditional PET systems. The system has broad FDA clearance in the U.S. for imaging and measuring injected positron emitting radiopharmaceuticals. The current leading (reimburseable) indication is high resolution imaging of primary solid tumors for treatment planning, particularly as an adjunct to traditional staging PET/CT without additional radiotracer. The company is also pursuing targeted early detection of cancer and Alzheimer's disease with low-dose imaging in high-risk populations.
Something looks off?